Utang jangka cendhak marang ekuitas Mersana Therapeutics (MRSN)

The market capitalization trend for Mersana Therapeutics (MRSN) on the GURU.Markets platform is 0.00. Mersana Therapeutics (MRSN) generates revenue through the development of ADC drugs and strategic alliances with industry leaders. Meanwhile, the risk of disrupted logistics chains and challenges with international software patenting create a certain vulnerability. However, the humanitarian status of its developments in female oncology ensures the stability of US trials regardless of trade wars.

MRSN - Rasio utang jangka cendhak marang ekuitas Mersana Therapeutics ing rentang 04.07.2022 - 17.01.2026

Rincian metrik keuangan lan pasar Mersana (MRSN)

- kuotasi lan prakiraan analis:

Rega saham Mersana Therapeutics|MRSN - Prakiraan konsensus analis

- rincian kapitalisasi pasar:

Nilai pasar Mersana Therapeutics Inc|MRSN - Nilai Bisnis

- data ekuitas miturut neraca:

Nilai Buku saben Saham Mersana Therapeutics|MRSN - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku mersana.com|MRSN - Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Mersana Therapeutics|MRSN - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Mersana Therapeutics|MRSN - Kewajiban utang agregat|Utang marang nilai buku Mersana Therapeutics Inc|MRSN - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Mersana Therapeutics|Likuiditas cepet mersana.com

- statistik bathi lan rasio pasar:

MRSN - Penghasilan resik

Pambiji fundamental:Mersana Therapeutics, Inc. MRSN

This ratio measures the proportion of short-term liabilities relative to shareholders' equity, determining the liquidity and default risk of the company over the next twelve months. By analyzing the short-term debt to equity ratio, an investor assesses the financial stability of Mersana Therapeutics (MRSN) while scaling the Dolaflexin platform and developing innovative ADC drugs for ovarian cancer therapy.

Pesaing Mersana Therapeutics

Utang jangka cendhak marang modal MRUS|Utang jangka cendhak marang modal Immutep Corp (IMMP)|Utang jangka cendhak marang ekuitas Anixa Biosciences, Inc. ANIX|ATOS: Rasio utang jangka cendhak marang modal|Context Tx - Utang jangka cendhak marang modal|BriaCell Therapeutics Corp. (BCTX) - Rasio utang jangka cendhak marang ekuitas|EPIX: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal QT Imaging, Inc. (QTI)